About pirtobrutinib
Non-covalent Bruton tyrosine kinase inhibitor
Used for
- Treats mantle cell lymphoma after at least two prior systemic treatments, including a BTK inhibitor.
- Treats chronic lymphocytic leukemia or small lymphocytic lymphoma after prior systemic treatments, as approved locally.
Usual adult dose
200 mg by mouth once daily; dose may be reduced for side effects or interactions.
Common side effects
- Fatigue
- Diarrhea
- Bruising or bleeding
- Infections
Important warnings
- Serious bleeding can occur, including rarely fatal bleeding.
- Risk of serious infections; report fever or other infection symptoms promptly.
- May cause abnormal heart rhythms, including atrial fibrillation.
- Blood counts, liver tests, and signs of bleeding or infection may need monitoring.
Pregnancy
May harm an unborn baby. Effective contraception is recommended during treatment and for one week after the last dose.
Breastfeeding
Do not breastfeed during treatment and for one week after the last dose.
Interactions
- Strong or moderate CYP3A inhibitors can increase pirtobrutinib levels.
- Strong or moderate CYP3A inducers can reduce pirtobrutinib levels.
- May increase levels of some CYP2C8, CYP2C19, CYP3A, or P-glycoprotein substrate medicines.
- Blood thinners and antiplatelet medicines may increase bleeding risk.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.